MediWound to Announce Q2 2024 Financial Results

MediWound Ltd. (Nasdaq: MDWD), a prominent player in the field of innovative enzymatic therapeutics for tissue repair, is set to unveil its financial results for the second quarter of 2024. The announcement is scheduled for Wednesday, August 14, 2024. Following the release, the company’s management will conduct a conference call and live webcast at 8:30 am Eastern Time to delve into the financial results, provide updates on corporate activities, and address questions from participants.

Participants interested in joining the conference call can use the following dial-in numbers: for toll-free access, dial 1-833-630-1956; for calls from Israel, dial 1-80-921-2373; and for international calls, dial 1-412-317-1837. To ensure timely participation, callers are advised to dial in at least five minutes before the call begins. Additionally, the webcast will be archived and made available for replay in the Investors section of the MediWound website.

MediWound Ltd. is globally recognized for its innovative approach to non-surgical tissue repair through enzymatic therapeutics. The company is dedicated to developing, producing, and commercializing swift and efficient biologics that not only enhance the current standards of medical care but also improve patient experiences and reduce unnecessary medical costs and surgeries.

One of the cornerstone products of MediWound is NexoBrid®, a biologic approved by both the FDA and EMA for the removal of eschar in patients with deep partial-thickness and full-thickness thermal burns. This product has been shown to significantly decrease the need for surgical interventions. Building on its core enzymatic technology platform, MediWound has established a robust research and development pipeline. This includes EscharEx®, the company’s leading drug currently under development. EscharEx® is a biologic poised for Phase III clinical trials aimed at the debridement of chronic wounds. It promises substantial benefits over existing products in the $360+ million market and holds potential for market expansion.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!